Kohei Kitagawa, Shusuke Uekusa, Yuki Hanai, Itsuki Kimura, Masaru Tsukahara, Azusa Kagawa, Kenji Sasaoka, Yui Sakishiro, Ayaka Miyake, Yuki Watanabe, Daiki Baba, Masafumi Kodama, Yoshiki Kishi, Norihito Yamada, Takashi Yoshio, Kazuhiro Matsuo
Psychopharmacotherapy for patients with schizophrenia in Japan has a long history of polypharmacy, which is rare worldwide but remains a critical problem. One reason for this is that clozapine was not available in Japan until 2009. We aimed to investigate the changes in psychopharmacotherapy in patients with schizophrenia over 12 years pre- and post-introduction of clozapine to clarify how psychopharmacotherapy for patients with schizophrenia has changed with the introduction of clozapine. We retrospectively collected data from the medical records of inpatients diagnosed with schizophrenia at the Okayama Psychiatric Medical Center...
April 9, 2024: Asian Journal of Psychiatry